Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PHAT · NASDAQ · Pharmaceutical Preparations
$4.66−0.42 (−8.27%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Phathom Pharmaceuticals (PHAT) · oqro.io/stocks/PHAT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
5%+ stake, activist · Stake as of Oct 29, 2026 · Filed Nov 2, 2026
James N. Topper disclosed a 7.4% stake in PHAT and may seek to influence the companySourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 15, 2026
Divisadero Street Capital Management, LP no longer reported PHAT for Q1 2026SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 17, 2026
Divisadero Street Capital Management, LP disclosed a new position in PHAT for Q4 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Oct 20, 2025
Simplify Asset Management Inc. disclosed a reduced position in PHAT for Q3 2025SourceInsider trade · Traded Sep 5, 2025 · Filed Sep 9, 2025
Officer sold ~$5.6K of PHAT shares in the open marketSourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 14, 2025
Frazier Life Sciences Management, L.P. disclosed an increased position in PHAT for Q2 2025SourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 7, 2025
Simplify Asset Management Inc. disclosed a reduced position in PHAT for Q2 2025SourceInsider trade · Traded Jul 16, 2025 · Filed Jul 18, 2025
Officer sold ~$14K of PHAT shares in the open marketSourceInsider trade · Traded May 21, 2025 · Filed May 23, 2025
Director purchased ~$15K of PHAT shares in the open marketSourceInsider trade · Traded May 14, 2025 · Filed May 15, 2025
Director purchased ~$21K of PHAT shares in the open marketSourceInsider trade · Traded May 13, 2025 · Filed May 15, 2025
Director purchased ~$3.5K of PHAT shares in the open marketSourceInsider trade · Traded May 12, 2025 · Filed May 13, 2025
Director purchased ~$38K of PHAT shares in the open marketSourceInsider trade · Traded Apr 7, 2025 · Filed Apr 8, 2025
CFO sold ~$17K of PHAT shares in the open marketSourceInsider trade · Traded Mar 13, 2025 · Filed Mar 17, 2025
Director purchased ~$44K of PHAT shares in the open marketSourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Orbimed Advisors LLC no longer reported PHAT for Q4 2024SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Gilder Gagnon Howe & Co LLC disclosed a reduced position in PHAT for Q4 2024SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 13, 2025
Kennedy Capital Management LLC no longer reported PHAT for Q4 2024SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 11, 2025
Simplify Asset Management Inc. disclosed an increased position in PHAT for Q4 2024Insider trade · Traded Jan 21, 2025 · Filed Jan 23, 2025
CEO sold ~$126K of PHAT shares in the open marketSourceInsider trade · Traded Jan 21, 2025 · Filed Jan 23, 2025
CFO sold ~$43K of PHAT shares in the open marketSourceInsider trade · Traded Jan 21, 2025 · Filed Jan 23, 2025
Officer sold ~$52K of PHAT shares in the open marketSourceInsider trade · Traded Dec 19, 2024 · Filed Dec 20, 2024
CFO sold ~$10K of PHAT shares in the open marketSourceInsider trade · Traded Dec 19, 2024 · Filed Dec 20, 2024
Officer sold ~$8.9K of PHAT shares in the open marketSourceInsider trade · Traded Dec 13, 2024 · Filed Dec 16, 2024
Director purchased ~$99K of PHAT shares in the open marketSourceInsider trade · Traded Dec 13, 2024 · Filed Dec 16, 2024
Director purchased ~$81K of PHAT shares in the open marketSourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Nov 14, 2024
Orbimed Advisors LLC disclosed a new position in PHAT for Q3 2024SourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Nov 14, 2024
Gilder Gagnon Howe & Co LLC disclosed an increased position in PHAT for Q3 2024SourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Nov 14, 2024
Kennedy Capital Management LLC disclosed a reduced position in PHAT for Q3 2024SourceInsider trade · Traded May 9, 2025 · Filed May 13, 2025
Director purchased ~$107K of PHAT shares in the open marketSourceInsider trade · Traded May 9, 2025 · Filed May 13, 2025
Director purchased ~$8.1K of PHAT shares in the open marketSourceInsider trade · Traded May 6, 2025 · Filed May 8, 2025
Director purchased ~$13K of PHAT shares in the open marketSourceInsider trade · Traded May 7, 2025 · Filed May 8, 2025
Director purchased ~$12K of PHAT shares in the open marketSource